Efficacy and Cost-effectiveness of Promotion Methods to Recruit Participants to an Online Screening Registry for Alzheimer Disease Prevention Trials: Observational Study.
Alzheimer
Trial-Ready Cohort
advertisement
clinical trial
cost-effectiveness
dementia
online clinical study
preclinical Alzheimer disease
promotion
recruitment
Journal
Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882
Informations de publication
Date de publication:
22 07 2021
22 07 2021
Historique:
received:
05
12
2020
accepted:
24
05
2021
revised:
03
02
2021
entrez:
22
7
2021
pubmed:
23
7
2021
medline:
26
10
2021
Statut:
epublish
Résumé
Web-based screening may be suitable for identifying individuals with presymptomatic latent diseases for recruitment to clinical studies, as such people do not often visit hospitals in the presymptomatic stage. The promotion of such online screening studies is critical to their success, although it remains uncertain how the effectiveness of such promotion can differ, depending on the different promotion methods, domains of interest, or countries of implementation. The Japanese Trial-Ready Cohort (J-TRC) web study is our ongoing online screening registry to identify individuals with presymptomatic Alzheimer disease (AD), aimed at facilitating the clinical trials for AD prevention. Within the first 9 months of its 2019 launch, the J-TRC web study recruited thousands of online participants via multiple methods of promotion, including press releases, newspaper advertisements, web advertisements, or direct email invitations. Here, we aimed to quantitatively evaluate efficacy and cost-effectiveness of each of these multimodal promotion methods. We applied the vector-autoregression model to assess the degree of contribution of each type of promotion to the following target metrics: number of daily visitors to the J-TRC website, number of daily registrants to the J-TRC web study, daily rate of registration among visitors, daily rate of eligible participants among registrants, and median age of daily registrants. The average cost-effectiveness for each promotion method was also calculated using the total cost and the coefficients in the vector-autoregression model. During the first 9 months of the reviewed period from October 31, 2019 to June 17, 2020, there were 48,334 website visitors and 4429 registrations (9.16% of 48,334 visitors), of which 3081 (69.56%) were eligible registrations. Initial press release reports and newspaper advertisements had a marked effect on increasing the number of daily visitors and daily registrants. Web advertisements significantly contributed to the increase in daily visitors (P<.001) but not to the daily registrants, and it also lowered the rate of registrations and the median age of daily registrants. Website visitors from the direct email invitation sent to other cognitive registries seem to have registered with the highest reliability. The calculated average cost-effectiveness for the initial press release was US $24.60 per visitor and US $96.10 per registrant, while the calculated average cost-effectiveness for the newspaper advertisements was US $28.60 per visitor and US $227.90 per registrant. Our multivariate time-series analysis showed that each promotion method had different features in their effect of recruiting participants to the J-TRC web study. Under the advertisement condition settings thus far, newspaper advertisements and initial press releases were the most effective promotion methods, with fair cost-effectiveness that was equivalent to earlier online studies. These results can provide important suggestions for future promotions for the recruitment of presymptomatic participants to AD clinical trials in Japan.
Sections du résumé
BACKGROUND
Web-based screening may be suitable for identifying individuals with presymptomatic latent diseases for recruitment to clinical studies, as such people do not often visit hospitals in the presymptomatic stage. The promotion of such online screening studies is critical to their success, although it remains uncertain how the effectiveness of such promotion can differ, depending on the different promotion methods, domains of interest, or countries of implementation.
OBJECTIVE
The Japanese Trial-Ready Cohort (J-TRC) web study is our ongoing online screening registry to identify individuals with presymptomatic Alzheimer disease (AD), aimed at facilitating the clinical trials for AD prevention. Within the first 9 months of its 2019 launch, the J-TRC web study recruited thousands of online participants via multiple methods of promotion, including press releases, newspaper advertisements, web advertisements, or direct email invitations. Here, we aimed to quantitatively evaluate efficacy and cost-effectiveness of each of these multimodal promotion methods.
METHODS
We applied the vector-autoregression model to assess the degree of contribution of each type of promotion to the following target metrics: number of daily visitors to the J-TRC website, number of daily registrants to the J-TRC web study, daily rate of registration among visitors, daily rate of eligible participants among registrants, and median age of daily registrants. The average cost-effectiveness for each promotion method was also calculated using the total cost and the coefficients in the vector-autoregression model.
RESULTS
During the first 9 months of the reviewed period from October 31, 2019 to June 17, 2020, there were 48,334 website visitors and 4429 registrations (9.16% of 48,334 visitors), of which 3081 (69.56%) were eligible registrations. Initial press release reports and newspaper advertisements had a marked effect on increasing the number of daily visitors and daily registrants. Web advertisements significantly contributed to the increase in daily visitors (P<.001) but not to the daily registrants, and it also lowered the rate of registrations and the median age of daily registrants. Website visitors from the direct email invitation sent to other cognitive registries seem to have registered with the highest reliability. The calculated average cost-effectiveness for the initial press release was US $24.60 per visitor and US $96.10 per registrant, while the calculated average cost-effectiveness for the newspaper advertisements was US $28.60 per visitor and US $227.90 per registrant.
CONCLUSIONS
Our multivariate time-series analysis showed that each promotion method had different features in their effect of recruiting participants to the J-TRC web study. Under the advertisement condition settings thus far, newspaper advertisements and initial press releases were the most effective promotion methods, with fair cost-effectiveness that was equivalent to earlier online studies. These results can provide important suggestions for future promotions for the recruitment of presymptomatic participants to AD clinical trials in Japan.
Identifiants
pubmed: 34292159
pii: v23i7e26284
doi: 10.2196/26284
pmc: PMC8367100
doi:
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e26284Informations de copyright
©Kenichiro Sato, Yoshiki Niimi, Ryoko Ihara, Kazushi Suzuki, Tatsushi Toda, Atsushi Iwata, Takeshi Iwatsubo. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 22.07.2021.
Références
Alzheimers Dement. 2019 Jan;15(1):172-178
pubmed: 29936146
J Med Internet Res. 2019 Mar 9;21(5):e11492
pubmed: 31066715
J Hypertens. 2017 Dec;35(12):2527-2531
pubmed: 28704263
Eval Program Plann. 2006 Nov;29(4):433-40
pubmed: 17950873
Soc Psychiatry Psychiatr Epidemiol. 2021 Jan;56(1):165-167
pubmed: 33034669
JAMA Neurol. 2014 Aug;71(8):961-70
pubmed: 24886908
J Med Internet Res. 2008 Dec 15;10(5):e50
pubmed: 19073542
Int J Methods Psychiatr Res. 2014 Jun;23(2):184-91
pubmed: 24615785
Clin Trials. 2018 Apr;15(2):130-138
pubmed: 29361843
BMJ Open. 2013 Feb 07;3(2):
pubmed: 23396504
J Med Internet Res. 2012 Feb 01;14(1):e20
pubmed: 22297093
J Prev Alzheimers Dis. 2020;7(4):208-212
pubmed: 32920621
Trials. 2019 Jun 19;20(1):366
pubmed: 31217024
Internet Interv. 2014 Apr;1(2):58-64
pubmed: 25045624
J Med Internet Res. 2013 Feb 12;15(2):e31
pubmed: 23403043
Lancet Neurol. 2013 Feb;12(2):207-16
pubmed: 23332364
Nicotine Tob Res. 2006 Dec;8 Suppl 1:S35-41
pubmed: 17491169
Am J Med Sci. 2020 Sep;360(3):213-215
pubmed: 32690272
J Med Internet Res. 2012 Feb 23;14(1):e28
pubmed: 22360969
Lancet Neurol. 2016 Jun;15(7):661-662
pubmed: 27302232
J Med Internet Res. 2016 Jun 15;18(6):e117
pubmed: 27306780
J Med Internet Res. 2019 Mar 25;21(3):e11286
pubmed: 30907739
Alzheimers Dement (N Y). 2021 Mar 24;7(1):e12135
pubmed: 33778148
Br J Clin Pharmacol. 2014 Jun;77(6):1064-72
pubmed: 24283948
J Med Internet Res. 2015 Jul 22;17(7):e183
pubmed: 26202991
Alzheimers Dement. 2019 Apr;15(4):515-524
pubmed: 30772251
Trials. 2016 Sep 26;17(1):467
pubmed: 27669823
JMIR Res Protoc. 2018 Jan 24;7(1):e20
pubmed: 29367186
Alzheimers Dement. 2011 May;7(3):280-92
pubmed: 21514248
Contemp Clin Trials. 2010 Sep;31(5):447-56
pubmed: 20601159
Addict Behav. 2013 Oct;38(10):2473-6
pubmed: 23770645